Provectus Biopharmaceuticals, Inc.
PVCT
$0.0749
-$0.0042-5.31%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 657.60K | 617.10K | 723.90K | 683.90K | 590.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 657.60K | 617.10K | 723.90K | 683.90K | 590.70K |
| Cost of Revenue | 1.79M | 1.96M | 1.81M | 1.75M | 1.71M |
| Gross Profit | -1.13M | -1.34M | -1.09M | -1.07M | -1.12M |
| SG&A Expenses | 3.52M | 2.61M | 1.08M | 990.60K | 930.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.31M | 4.56M | 2.90M | 2.74M | 2.64M |
| Operating Income | -4.65M | -3.95M | -2.17M | -2.06M | -2.05M |
| Income Before Tax | -5.42M | -4.76M | -3.03M | -2.79M | -2.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.42 | -4.76 | -3.03 | -2.79 | -2.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 21.50K | -- | -- | -- | -- |
| Net Income | -5.40M | -4.76M | -3.03M | -2.79M | -2.78M |
| EBIT | -4.65M | -3.95M | -2.17M | -2.06M | -2.05M |
| EBITDA | -4.65M | -3.94M | -2.16M | -2.05M | -2.04M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Average Diluted Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |